Disrupting key cancer pathways to prevent disease growth and survival


Dual Therapeutics is an oncology company developing novel therapeutics for prostate cancer, lung cancer, and acute lymphoblastic leukemia. Founded in 2013, the company’s technology is based on research developed and exclusively licensed from the Mount Sinai School of Medicine and Case Western Reserve University. In 2016, Dual Therapeutics partnered with BMS in a strategic collaboration to advance its compounds for the treatment of cancer and other diseases.




Read more on the development of our novel therapeutics.

Learn More →


Get to know our drug development experts.

Learn More →